Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDex vs BMDex in AL Amyloidosis
NCT01277016Phase 3Completed
- Start
- Jan 2011
- Primary completion
- Feb 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib in amyloid light chain amyloidosis (2 arms). Primary endpoint: Number of Patients in CR and PR measured by level of serum light chain monoclonal protein. Started Jan 2011; status: completed.
02
Drugs
bortezomib
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT01277016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01277016.